Feasibility and safety of left atrial posterior wall isolation with a new Cryoballoon technology in patients with persistent atrial fibrillation

Antonio Bisignani¹, Luigi Pannone², Vincenzo Miraglia³, Juan Sieira⁴, Saverio Iacopino⁵, Gezim Bala³, Erwin Stroker⁶, Ingrid Overeinder⁷, Alexandre Almorad³, Anaïs Gauthey³, Cinzia Monaco³, Gaetano Paparella⁸, Thiago Guimarães Osório⁸, Antonio Sorgente⁹, Luc Jordens¹⁰, Pedro Brugada¹¹, Gian battista Chierchia¹², and Carlo de Asmundis¹³

¹Policlinico Universitario Agostino Gemelli
²IRCCS Ospedale San Raffaele
³Vrije Universiteit Brussel
⁴UZ Brussel
⁵Villa Maria Cecilia
⁶Universitair Ziekenhuis Brussel
⁷UZ Brussel, Vrije Universiteit Brussel
⁸Heart Rhythm Management Center, Cardiovascular Center UZ Brussel Vrij Universiteit Brussel, Dpt Cardiology laarbeeklaan 101 Brussel, Jette, BE 1090 0032-2-4763038, Cardiology Brussels, BE 0032-2-4763038
⁹Cleveland Clinic Abu Dhabi
¹⁰Erasmus MC
¹¹Free University of Brussels
¹²heart rhythm management center
¹³UZ Brussel-VUB

November 16, 2021

Abstract

Introduction: Left atrial posterior wall isolation (LAPWI) is often performed in addition to pulmonary vein isolation (PVI) to improve outcome in patients with persistent atrial fibrillation (AF). In this setting, LAPWI + PVI using cryoballoon ablation had comparable results with radiofrequency ablation (RFA). The aim of the study is to evaluate the feasibility and safety of a new cryoballoon ablation system in PVI + LAPWI isolation, comparing it with the historical platform. Methods: The study was a prospective, non-randomized, single center study. Forty consecutive patients, undergoing PVI + LAPWI with the novel POLARx, were compared to 40 consecutive patients who underwent the same procedure with the established Arctic Front Advance PRO. Results: Acute isolation was achieved in all PVs in both groups and LAPWI was achieved in 38 patients (95%) in the POLARx group and in 36 patients (90%) in Arctic Front group. Procedural outcomes were similar between the two groups, except for lower temperatures during cryoapplications in the POLARx group, for both PVI and LAPWI. The complication rate was low and similar between groups. Conclusion: LAPWI+PVI with the novel POLARx Cryoballoon is feasible and safe; the results are comparable with the Arctic Front Advance PRO system.

Hosted file
